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Abstract
Background and objective. Nocturnal leg cramps (NLC) are common in primary care and may 
cause severe pain and sleep disturbance. We systematically reviewed the effectiveness of mag-
nesium in treating NLC and the side-effect profile of magnesium compared to placebo.
Methods. We searched Medline, Embase, Cochrane Library, ClinicalTrials.gov, the International 
Standard Randomised Controlled Trial Number and the International Clinical Trials Registry 
Platform registries until August 2012. All randomized controlled trials (RCTs) comparing mag-
nesium therapy for NLC in adults with any other comparator were eligible. Two investigators 
independently selected, extracted data from and rated the risk of bias of relevant studies. To 
compensate for the heterogeneity in outcome measures, simulations were used to summarize 
the data.
Results. Seven RCTs were included in the review (n = 361), all comparing magnesium to pla-
cebo. Three of these trials included only pregnant women. The difference in the median number 
of leg cramps per week between the placebo and the intervention groups was 0.345 (quan-
tile 2.5%: −0.133, quantile 97.5%: 0.875). This difference was 0.807 (quantile 2.5%: 0.015, quan-
tile 97.5%: 1.207) in the three studies involving only pregnant women and 0.362 (quantile 2.5%: 
−0.386, quantile 97.5%: 1.148) in the others. Overall gastrointestinal side effects were slightly 
more common with magnesium therapy than with placebo. The strength of this evidence was 
weak, mainly due to small study sizes and short follow-up.
Conclusions. Magnesium therapy does not appear to be effective in the treatment of NLC in the 
general population, but may have a small effect in pregnant women. Further research using bet-
ter designed RCTs is necessary.
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Introduction
Nocturnal leg cramps (NLC) are defined as painful involuntary 
contractions of the lower limbs occurring during prolonged 
periods of rest, typically during the night (1). They may cause 
severe pain and sleep disturbance, and are particularly common 
among older adults, though they can occur in all decades of life 
(1–3). They are frequently unreported to physicians (2,4,5). In a 
general population survey carried out in the UK (n = 233), the 
overall prevalence of NLC was 37%, but the disorder was more 
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prevalent in older subjects (>80 years old: 54%) (2). Of those 
who experienced NLC, 40% had cramps three or more times 
per week and 6% nightly. Another study performed in older US 
veterans (n = 515) showed that 56% suffered from NLC (6). The 
disorder is also common in pregnancy, experienced by up to 50% 
of pregnant women (1,7–9). Leg cramps occur most often during 
the third trimester and do not seem to be related with pregnancy 
complications or unfavourable foetal outcomes (9,10).
The precise cause of these cramps is unclear. Most NLC occur-
ring in adults appear to be idiopathic, but potential contribut-
ing factors include low levels of certain minerals, extracellular 
fluid volume depletion and prolonged sitting or inappropriate 
leg position during sedentary activity (1). Various neurologic, 
endocrine, metabolic, vascular, medication-related, toxic and 
congenital conditions can also predispose to NLC, which may 
then respond to specific treatment (such as a change in medica-
tion for medication-related NLC) (1). People with these condi-
tions are often excluded from therapeutic trials.
Quinine, the only treatment proven to be effective, may result 
in serious and/or life-threatening side effects, such as haemo-
lytic–uraemic syndrome, disseminated intravascular coagulation 
or cardiac arrhythmias (1,3,11–13). Because of its unfavourable 
risk-to-benefit ratio the Food and Drug Administration recently 
recommended against using quinine for treating NLC (1,14,15).
Magnesium plays an important role in hundreds of metabolic 
reactions and in muscle function (16–18). Magnesium deficiency 
can result from chronic diseases (e.g.: alcoholism, malabsorp-
tion), medication use (e.g.: diuretics), pregnancy and poor nutri-
tion (17,19–22). Elderly people are particularly at risk, because 
of the combination of chronic diseases, poor nutrition, decreased 
absorption of magnesium and increased renal exertion (17). 
As magnesium deficiency leads to neuronal excitability and 
enhances neuromuscular transmission (1,23–25), and since its 
substitution has been shown to be effective in eclampsia-related 
seizures (17,26–29), some authors have suggested a beneficial 
role of magnesium in NLC.
Young et al. (3,30) carried out two systematic reviews on a 
variety of interventions in NLC. The only treatment, in addition 
to quinine, which showed a statistically significant effect was 
magnesium in pregnant women (but not in the general popula-
tion). This conclusion rested on low-quality evidence as only one 
randomized controlled trial (RCT) was included in the system-
atic review and only short-term outcomes were assessed (19).
Because it has a favourable side-effect profile, magnesium has 
become the cornerstone of treatment of leg cramps, particularly 
in Europe, despite this lack of evidence (1).
The present systematic review was designed to close the gap 
in our knowledge on the potential role of magnesium therapy 
in NLC. Through a critical appraisal and synthesis of relevant 
RCTs, including new studies undertaken since the last review, 
the objectives were to assess the effectiveness of this therapy, 
mainly in reducing the number of NLC per week, in pregnant 
women and in the general adult population, and to assess the 
side-effect profile of magnesium compared to placebo.
Methods
Design and search strategy
We conducted a systematic review of the literature through the 
electronic databases Medline, Embase and Cochrane Library (from 
inception to the end of August 2012), using the key words ‘magne-
sium and (leg or legs) and (cramp or cramps)’, without any limits. 
The archives of the ClinicalTrials.gov registry, the International 
Standard Randomised Controlled Trial Number registry and the 
International Clinical Trials Registry Platform of the World Health 
Organization were consulted to identify unpublished clinical tri-
als (using the key words ‘magnesium’ and ‘cramps’) and authors 
contacted to obtain additional data where necessary. The reference 
lists of all relevant papers were also scanned and local specialists 
in internal medicine, neurology and nutrition were contacted for 
information about any other published or unpublished trial that 
they might be aware of. The identification of relevant studies and 
the extraction of the data were carried out independently by two 
investigators (PS, DMH) in duplicate. Doubts and disagreements 
were resolved by discussion and consensus.
Study eligibility
All RCTs, assessing the effect of magnesium against any other 
comparator on NLC in pregnant women or in the general adult 
population (i.e. men and/or non-pregnant women) were eligible 
for inclusion. No language, publication date (or completion date 
for unpublished studies) or setting restrictions were applied, but 
studies in prepubertal children were excluded. We based the 
definition of NLC on the diagnostic criteria of the American 
Academy of Sleep Medicine (see panel).
Panel: Diagnostic criteria for NLC as published by the 
American Academy of Sleep Medicine (2005) (1):
1. The painful sensation in the leg or foot is associated with 
sudden muscle hardness or tightness, indicating a strong 
muscle contraction.
2. The painful muscle contractions in the legs or feet occur 
during the sleep period, though they may arise from either 
wakefulness or sleep.
3. The pain is relieved by forceful stretching of the affected 
muscles, releasing the contraction.
4. The sleep-related leg cramps are not better explained by 
another current sleep disorder, medical or neurologic disor-
der, medication use or substance use disorder.
Trials assessing treatments for exertion cramps, restless legs 
syndrome, periodic limb movements, vascular claudication, 
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peripheral neuropathy and dystonia, as well as trials of treat-
ments for cramps not located in the legs were excluded.
Data extraction
The following data were obtained from all the retrieved studies: 
design (parallel or cross over), details of the population (country, 
setting, pregnant women or general population, mean age and 
range, gender, number of subjects followed up, number lost to 
follow-up and number having refused to participate), type and 
dose of magnesium as well as length of treatment, criteria for 
eligibility, outcome measures used to assess the effectiveness of 
magnesium compared to placebo and side effects.
Data quality assessment
The two reviewers independently assessed the quality of the 
papers using Crombie’s check list and the Cochrane collaboration 
standard criteria (31,32). A  summary assessment was prepared 
for each study across the following domains: sequence genera-
tion; allocation concealment; selection and attrition bias; blinding 
of participants and research staff; blinding of outcome assessors; 
sample size estimate; description of study population, design and 
measurements; analysis by intention to treat and assessment of 
statistical significance; role of funding body or industry; reporting 
of side effects of treatment; main study limitations. Doubts and 
disagreements were resolved by discussion and consensus.
Data analysis
A critical appraisal and synthesis of all relevant RCTs were per-
formed. As NLC were measured in a large variety of ways (mean 
or median; number of days and/or nights with cramps or num-
ber of cramps), outcome data could not be summarized using 
conventional meta-analytic methods. In addition, the differences 
between the studies were important regarding the study popula-
tion (pregnant women or general population), the study design 
(parallel or cross-over RCTs), the type of magnesium (oral or 
intravenous magnesium), the dose and length of treatment.
Monte Carlo simulations were therefore used in an attempt 
to overcome this heterogeneity in designs, primary outcomes 
and methods of summarizing these outcomes. When little infor-
mation was available regarding data distribution, and because 
the distribution of leg cramps was usually highly asymmetric, 
we simulated the data from a log normal distribution so that 
the mean or the median, and the standard deviation fitted the 
reported data. Details of these simulations for each study can 
be found in the appendix (See online supplementary Table S1).
The cycle of simulation was repeated 10 000 times, and the 
main outcome was difference between the median number of 
cramps per week in the magnesium group and the median in 
the placebo group after the intervention. For each of the 10 000 
simulations, the difference in the medians of each group was 
stored for each study, for the subset of studies dealing with 
pregnant women, for the subset of studies dealing with non-
pregnant patients and for the entire set of patients. This allowed 
the estimation of 2.5%, 50% and 97.5% quantiles of the dif-
ference between the intervention and the control groups. All the 
analyses were undertaken using TIBCO Spotfire S+® 8.2 for 
Windows, TIBCO Software Inc., Palo Alto, CA.
This systematic review was carried out in accordance with 
the Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) guidelines (33). Assessment of publication 
bias was not performed because of the great heterogeneity and 
the overall small sample size of the studies included in the review.
Results
The study selection process is summarized in Figure 1. Six RCTs, 
involving a total of 321 patients, were retrieved through the elec-
tronic databases search (9,19,24,34–36), and one additional 
unpublished RCT (n  =  40) was identified in the archives of the 
ClinicalTrials.gov registry (Table 1) (37). Table 2 presents the inclu-
sion and exclusion criteria for the population involved in the trials.
The study population was restricted to pregnant women in 
three studies, whereas in the remaining four studies the outcomes 
were assessed in general populations. Two studies used a cross-
over design. The sample sizes for all studies were small: the highest 
total number of subjects followed up was 80. In comparison to the 
number followed up attrition was particularly high in two stud-
ies [number lost to follow-up/number followed up (%) = 27/46 
(59%) in Roffe’s and 7/38 (18%) in Nygaard’s trials]. The number 
declining to participate was not stated in four studies and was high 
in two studies in comparison to the number followed up (number 
declining participation/number followed up (%) = 47/42 (112%) 
in Frusso’s and 17/46 (37%) in Garrison’s trials).
Type of magnesium treatment
One trial assessed magnesium therapy in infusion (4 hours for 
five consecutive days), whereas the others evaluated oral magne-
sium therapy, all against placebo. The type, dose and length of 
magnesium therapy (5 days to 6 weeks) were very different from 
one trial to another.
Quality of the studies
Overall, the quality of the evidence was poor with all studies pre-
senting high risks of bias and lack of precision due to small sam-
ple sizes (Table 3). In particular, risks of selection, allocation and 
attrition bias were present or suspected to some extent in all stud-
ies. Many details were missing from the available reports in three 
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studies, including the unpublished trial, the author of which did 
not respond to our request for additional information (19,24,37). 
All the studies had only short-term follow-ups. Only the two stud-
ies carried out by Garrison and by Supakatisant could be consid-
ered as being at low risk of bias in terms of the role of the funding 
body or industry. Note that two studies used a cross-over design 
providing more precise comparisons and therefore requiring fewer 
subjects to achieve the same precision (because each individual is 
considered as his/her own control), but making the analyses more 
difficult to be interpreted because of residual effects (carry-over 
effects) (24,34,38). Support for the reviewers’ judgements is pre-
sented in the appendix (See online supplementary Table S2).
Effect of magnesium treatment on the number or 
severity of NLC
As the data presented in the four older papers were insufficient 
to allow calculation of effect measures with 95% confidence 
interval (CI), we present summary measures for the two groups 
and P values (Table 4). Only two studies, both involving preg-
nant women, showed a statistically significant effect of magne-
sium therapy with a larger reduction in the number and severity 
of NLC in the intervention group compared to the placebo 
group (19,36). The third study in a pregnant population (n = 38) 
found no difference in outcomes between women receiving mag-
nesium and those exposed to placebo (9).
Effect on other outcomes
Two studies reported patient self-evaluation of the effective-
ness of treatment as an outcome. In both studies, the propor-
tion of patients reporting that the treatment was effective was 
significantly higher in the group receiving magnesium (Table 4) 
(19,34). Only one study examined cramp-related sleep distur-
bances and it found no effect of magnesium treatment on this 
outcome (24).
153 references identified through database 
searching
(Medline = 25, Embase = 109, Cochrane 
Library = 8, ClinicalTrials.gov registry = 6, 
ISRCTN registry = 1, ICTRP registry = 4)
2 additional references identified in 
bibliography of key articles
121 titles and abstracts screened for 
relevance after duplicates removed
104 articles excluded 
(irrelevant to the topic and/or reviews)
17 full-text articles 
assessed for eligibility
10 articles excluded 
(uncontrolled trials=5, observational 
study=1, review=2, letter=1, full record 
could not be retrieved=1)
7 studies included in the 
qualitative synthesis and in 
the meta-analysis
Figure 1. Flow chart for selection of studies, with indication of main reasons for exclusion.
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Table 1. Characteristics of RCTs of magnesium in nocturnal leg cramps (Mg = magnesium group, Plac = placebo group, CO = cross-
over design, NK = information not provided in the paper) 
References Study participants 
with nocturnal 
leg cramps, and 
setting
Design Mean age (range 
or SD)
Number 
followed up, 
total (women)
Loss to FU, 
total (%a)
Number 
refusing to 
participate
Type and 
dose of 
magnesium 
per day
Length of 
treatment 
and FU
Outcome 
measures
Mg Plac
Dahle  
(1995) (19)
Pregnant women 
referred from two 
prenatal care units 
in Sweden (n = 73)
Parallel NKb 34 (34) 35 (35) 4 (6) NK Mg citrate 
lactate 
360 mg 
(15 mmol)
3 weeks, FU 
3 weeks
Number 
of cramps, 
severity, 
subjective 
assessment
Frusso 
(1999) (24)
Patients referred 
by family doctors 
at a University- 
based ambulatory 
clinic in Argentina 
(n = 45)
CO 62 (28–87) NKc NKc 3 (7) 47 Mg citrate 
1800 mg 
(72 mmol)
Two periods 
of 30 days 
separated 
by washout 
period of 
30 days, FU 
after the two 
periods
Number 
of cramps, 
severity, 
duration, 
sleep 
disturbances
Roffe  
(2002) (34)
Subjects recruited 
by advertisements 
in the UK (n = 73)
CO Mg: 61 (11),  
Plac: 64 (10)
17 (11) 29 (14) 27 (59) NK Mg citrate 
300 mg 
(12 mmol)
Two periods 
of 6 weeks 
without 
washout 
period, FU 
after the final 
two periods 
of 4 weeks
Number 
of cramps, 
severity, 
duration, 
subjective 
assessment
Nygaard 
(2008) (9)
Pregnant women 
attending a 
routine ultrasound 
examination in 
Norway (n = 45)
Parallel Mg: 32 (4)d,  
Plac: 30 (3)d
21 (21) 17 (17) 7 (18) NK Mg citrate 
lactate 
360 mg 
(15 mmol)
2 weeks, FU 
2 weeks
Number 
of cramps, 
severity
Garrison 
(2011) (35)
Patients recruited 
by advertisements 
in the offices of 
family doctors and 
in newspapers in 
Canada (n = 46)
Parallel 69 (8) 24 (19) 22 (13) 0 17 Mg sul-
phate 5 g 
(20 mmol), 
4 hours 
infusion
5 days, FU 
30 dayse
Number 
of cramps, 
severity, 
duration
Supakatisant 
(2012) (36)
Pregnant women 
attending an ante-
natal care clinic in 
Thailand (n = 86)
Parallel Mg: 29 (6)f,  
Plac: 29 (5)f
41 (41) 39 (39) 6 (8) 9 Mg bis-
glycinate 
chelate 300 
mg
4 weeks, FU 
4 weeks
Number 
of cramps, 
severity
Rosenbaum 
(unpublished, 
completed in 
2009) (37)
Subjects recruited 
by radio advertise-
ments in the USA 
(n = 40)
Parallel 67 (10) 20 (10) 20 (13) 0 NK Mg lactate 
336 mg
6 weeks, FU 
4 weeks
Number 
of cramps, 
severity, 
duration,  
sleep 
disturbances
FU, follow-up.
aNumber lost to FU/number followed up.
bMean length of pregnancy of the 73 included subjects who started the study: 29 weeks (range 22–36 weeks); mean age not stated.
cTotal number of subjects followed up: 42; 73% women among the 45 included subjects who started the study.
dMean age of the 45 included subjects who started the study.
eIt is stated in the main text that the outcomes were also analysed after 3 months but FU data were only shown after 30 days.
fMean age of the 86 included subjects who started the study.
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Side effects
Table 5 lists the side effects reported in all the RCTs included 
in this review. The most frequent side effects in the trials using 
oral therapy concerned the gastrointestinal system (diarrohea, 
nausea, vomiting, flatulence and constipation). Injection-related 
side effects, but no gastrointestinal side effects, were reported in 
the trial using intravenous treatment (35). There was no statisti-
cally significant difference in the frequency of gastrointestinal 
side effects (P value 0.07). The mean difference was 0.13 (95% 
CI: −0.51 to 0.78), in favour of the placebo group. One severe 
side effect was reported: a stroke 31 days following a placebo 
infusion (35).
Simulations
As NLC outcome measures varied considerably from one study 
to another, standard meta-analysis could not be used to combine 
the results of these small trials. Simulations were therefore used, 
the results of which are shown in Figure 2.
The difference between the median number of cramps per 
week in the magnesium group and the median in the placebo 
group was 0.345 (quantile 2.5%: −0.133, quantile 97.5%: 
0.875). In other words, a median patient would get one cramp 
less every 3 weeks when magnesium is taken rather than a pla-
cebo. The three studies in a pregnant population had a median 
difference of 0.807 (quantile 2.5%: 0.015, quantile 97.5%: 
Table 2. Inclusion and exclusion criteria of RCTs of magnesium in nocturnal leg cramps 
Reference Inclusion criteria Exclusion criteria
Dahle (1995) (19) Pregnant women complaining of leg cramps 
during pregnancy
Information not provided in the paper
Frusso (1999) (24) ≥6 leg cramps in the previous month, ≥6 leg 
cramps after 4-week washout period with 
placebo, >18 years old, normal neurologic exam 
in legs
Alcohol abuse, psychiatric diseases, terminal 
disease, type 1 diabetes mellitus, renal failure, 
pregnancy, arteriopathy or neuropathy in legs, 
hypocalcaemia, hyponatraemia, hypokalaemia, 
not speaking Spanish, not having a telephone, 
inability to stop medications containing 
magnesium, low compliance
Roffe (2002) (34) ≥ 2 leg cramps per week for 3 months Unstable medical conditions known to affect 
cramp frequency, renal failure, pregnancy, 
terminal illness, recent change in drug treatment 
for quinine, diuretics, laxatives, beta agonist
Nygaard (2008) (9) Pregnant women, gestational age 18–35 weeks, 
18–38 years old, ≥ 2 leg cramps per week, no 
disease according to health certificate, Norwegian 
as first language
Twin pregnancy, oedema, pre-eclampsia, 
magnesium supplementation beyond the trial 
treatment
Garrison (2011) (35) ≥ 8 leg cramps in the previous month eGFR <50 ml/minute, atrioventricular nodal 
heart block or heart rate <54/minute without 
a pacemaker, previous myocardial infarction, 
congestive heart failure, digoxin use, significant 
neurologic disease, pregnancy, Addison’s disease, 
chronic hepatitis, significant abnormalities of 
serum calcium, sodium, potassium, chloride, 
bicarbonate, thyroid-stimulating hormone, alanine 
aminotransferase or prothrombin time
Supakatisant (2012) (36) Pregnant women, gestational age 14–34 weeks, 
≥2 leg cramps per week, no disease, no obstetrical 
complication, no treatment for leg cramps, no 
magnesium allergy
Multifoetal gestation, pregnancy-induced 
hypertension, preterm labour treated with 
tocolytic agent
Rosenbaum (unpublished, completed in 
2009) (37)
40–85 years old, no kidney impairment, ≥2 leg 
cramps per week in the previous month
Enrolled in another study, history of seizure dis-
order, current treatment with lithium or quinine, 
malabsorption or major intestinal disorders, 
significantly elevated magnesium level, history 
of significant diarrohea or drug/alcohol abuse, his-
tory of allergy to magnesium, currently diagnosed 
with a terminal illness
eGFR, estimated glomerular filtration rate.
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1.207), whereas the four others dealing with much older popu-
lations showed a median difference of 0.362 (quantile 2.5%: 
−0.386, quantile 97.5%: 1.148).
Discussion
Magnesium is widely prescribed in Europe and across the 
world to treat NLC (1). Yet uncertainty remains as to whether 
this treatment is beneficial (1,3,30). The aim of this systematic 
review was to clarify whether magnesium therapy is more effi-
cient than placebo in treating NLC. This critical appraisal of 
seven RCTs showed weak evidence in favour of the effective-
ness of magnesium in pregnant women, and unclear results in 
general populations. Meta-analysis using simulations confirmed 
the absence of a statistically significant effect of magnesium on 
the median number of leg cramps per week in general popula-
tions. A weak, but statistically significant effect was evidenced in 
pregnant populations. Yet the effect seemed small and the clini-
cal significance of these findings is uncertain. Oral magnesium 
was associated with gastrointestinal side effects and intravenous 
magnesium with burning at the intravenous site.
Young et al. (3,30) previously suggested that oral magnesium 
had different effects in pregnancy than in the general population. 
The treatments they investigated in their two systematic reviews 
included magnesium, calcium, multivitamins and mineral supple-
ments, sodium chloride and vitamin E for pregnant women, and 
quinine, analgesics, antiepileptic drugs, magnesium, vitamin E, 
compression hosiery and stretching exercises in the general pop-
ulation. Magnesium showed a statistically significant effect on 
the proportion of pregnant women reporting leg cramps, but no 
effect on NLC in the general population. This conclusion; how-
ever, rested on low-quality evidence due to the very low number 
of RCTs included and serious methodological limitations.
Our systematic review confirms that magnesium substitution 
is potentially beneficial in pregnant women but not in general, 
older populations. Garrison et al. (35) argues that this may be 
explained by differences in oral bioavailability of magnesium, the 
rate of magnesium absorption falling with age and by different 
Figure 2. Estimation of the median difference in the number of leg cramps per week between the placebo and the intervention group (with the quantiles 2.5% 
and 97.5%) obtained by simulation. The sizes of the squares that stand for the median effects are proportional to the number of patients in the study. Studies 
marked with * included only pregnant women.
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underlying aetiologies of NLC. Indeed, as pregnancy is a physi-
ological state of low serum magnesium (36), pregnancy-related 
NLC is more likely to be due to magnesium depletion. Magnesium 
therapy could therefore be more efficient in this population.
High risk of bias and small sample sizes in all the studies 
included in this review limit the strength of the evidence it pro-
vides. In particular, since insufficient information was avail-
able in Dahle’s and Nygaard’s papers regarding blinding (see 
Table  5), the results showing a potential effect of magnesium 
in pregnant women could be due to a placebo effect if blinding 
was inadequate. Follow-up periods were short, even though sub-
jects treated with oral magnesium often require relatively long 
treatments, because absorption of dietary magnesium decreases 
when dosage increases (ranges from 80% absorption at a low 
dietary intake to 10% at a high intake) and the steady state 
within tissue pools of magnesium is known to occur slowly 
(18,39). Finally, two studies included in the review used a cross-
over design. Although this may have provided more precise 
comparisons, using fewer subjects to achieve the same precision 
(each individual being considered as his/her own control), these 
studies carried additional risks of bias related to possible carry-
over effects (38).
The rate of magnesium absorption falls with age and var-
ies according to the type of magnesium preparation involved 
(35,40). The studies included individuals of many different ages 
and exposed them to a variety of different magnesium formula-
tions. This may also explain why, despite biological plausibility 
and a general tendency of most studies to show a larger reduction 
in cramps in the intervention compared to the placebo groups, 
pooled results could not provide evidence in favour of magne-
sium treatment. We can hypothesize that the lack of effectiveness 
partly results from the limited bioavailability of oral magnesium, 
mainly in elderly people. Another explanation for the negative 
results relates to selection bias with the inclusion of many sub-
jects whose leg complaints may have been confused with disor-
ders not known to be related to magnesium deficiency such as 
restless leg syndrome or vascular claudication, for example (1). 
None of the trials mentioned all these disorders in the exclusion 
criteria (and in one study, no exclusion criteria were stated).
As expected, oral magnesium was often associated with gas-
trointestinal side effects. However, the symptoms were relatively 
minor and the same reactions occurred in the placebo groups, 
though generally less frequently. In addition, no serious and/
or life-threatening adverse reaction was reported in relation to 
Table 5. Side effects reported in RCTs of magnesium in nocturnal leg cramps (nb = number, NK = information not provided in the 
paper) 
Reference Magnesium group Side effects (n or %) Placebo group Side effects (n or %)
Nb followed up Nb followed up
Dahle (1995)a (19) 34 Slight nausea (infrequent) 35 Slight nausea (infrequent), 
severe nausea (1)
Frusso (1999)a (24) NKb Diarrohea/nausea/vomiting 
(10.7%)
NKb Diarrohea/nausea/vomiting 
(10.1%)
Roffe (2002)c (34) 17 Diarrohea (14), constipation 
(6), nausea/indigestion/ 
flatulence (2), skin peeling (1)
29 Diarrohea (8), constipation 
(11), nausea/indigestion/ 
flatulence (4), bruising (1), 
headache (1)
Nygaard (2008)a (9) 21 Gastrointestinal side effects 
(nausea, flatulence, diarrohea, 
intestinal air) (6)
17 Gastrointestinal side effects 
(nausea, flatulence, diarrohea, 
intestinal air) (6)
Garrison (2011)a (35) 24 Asymptomatic hypotension 
(3), facial flushing (9), light- 
headedness (2), burning 
on the intravenous site 
(12) (five received normal 
saline solution to improve 
tolerability)
22 Facial flushing (7), on Day 31 
post-infusions: stroke (1)
Supakatisant (2012)d (36) 41 Nausea (11), diarrohea (6) 39 Nausea (6), diarrohea (1)
Rosenbaum (unpublished)a 
(37)
20 0 20 0
a95% CI and/or P values not provided in the paper.
bTotal nb of subjects followed up: 42.
cDiarrohea (P value 0.1); constipation (P value 0.2); nausea/indigestion/flatulence (P value 0.6).
dNausea (P value 0.3); diarrohea (P value 0.1).
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magnesium treatment. These data confirm that oral magnesium 
is safe.
Strengths and limitations of this review
To our knowledge, this is the first systematic review of RCTs 
in which a meta-analytical approach was used to examine the 
evidence in relation to magnesium therapy to treat NLC. Our 
review methods followed PRISMA guidelines. We searched trial 
registration databases in addition to publication databases, and 
interrogated experts in the field, thus limiting the risk of exclud-
ing unpublished trials from our review.
Potential limitations relate to missing information in the 
papers published before 2000 and in the unpublished trial, which 
we were unable to complete by contacting the authors. As the 
trials we retrieved were not sufficiently similar in terms of study 
population, design, type of treatment and outcome measures, we 
could not use traditional meta-analytical methods to pool the 
results. We used simulations to overcome the problem. As most 
outcome distributions were not normal, we had to consider the 
difference of medians between the placebo and the intervention 
population in these simulations, rather than the difference in 
means. This approach leads to higher uncertainty and potential 
sources of bias across studies. Also, our meta-analysis did not 
allow a weighting proportional to the precision of the estimates, 
but used a more basic weighting based on the number of patients.
Implications for clinical practice and future research
The evidence that can be extracted from the current review suffers 
from the relatively low methodological quality of the included 
trials. Yet it suggests magnesium treatment is efficient in treating 
NLC in pregnant women, though a difference of less than two 
cramps per week compared to placebo, as computed in our meta-
analysis, is probably not clinically significant. Although magne-
sium remains the cornerstone of NLC treatment across Europe 
and much of the world, this review highlights the lack of evidence 
that this treatment is truly effective outside pregnancy. Thus, there 
is no support for prescribing this treatment in everyday practice.
Physiopathology, patient feedback and clinical experience 
all concur to suggest that more research, less affected by bias, is 
needed to guide clinical practice in the future. New well-designed 
parallel group (or cross-over group, but with appropriate wash-
out periods) RCTs are urgently needed, since NLC are common 
and alter the quality of life of the patients suffering from this 
condition. They should include either pregnant women or non-
pregnant adults, exclude not only other conditions mimicking 
cramps (in particular, restless leg syndrome, periodic limb move-
ments, vascular claudication and peripheral neuropathy) but also 
secondary causes of NLC which are unlikely to respond to mag-
nesium substitution (e.g. NLC associated with other electrolytic 
abnormalities, such as hypocalcaemia or hyponatraemia). They 
should have sufficient power to allow a small-to-moderate real 
effect of magnesium therapy to be identified and have long-
term follow-ups to allow time for the treatment to be efficient 
(>3 months). Primary care physicians in particular, who see the 
majority of patients presenting with this condition, should be 
encouraged to include patients in well-designed trials that address 
the limitations of previous studies and provide reliable data in 
favour or against the routine use of magnesium as treatment for 
patients suffering from NLC. The main outcome that could be 
assessed in these future trials could be the decrease of the mean 
(or median) number of NLC per week in the two groups, com-
pared to baseline. These studies could also address a trade-off 
between a potential reduction of cramps and increase in gastro-
intestinal side effects related to the magnesium therapy. It would 
probably be useful to compare two different doses of the drug 
with the placebo in order to document the smallest effective dose.
In conclusion, this systematic review shows unclear results 
concerning the efficacy of magnesium therapy in the treatment of 
NLC in general populations and weak evidence in favour of this 
treatment for pregnancy-related NLC. This uncertainty results 
from relatively low methodological qualities of the trials included 
in the review. Further research using better designed RCTs is nec-
essary to confirm whether physicians may continue to use this 
treatment for their patients’ benefit. Before these trials are avail-
able, the routine use of this treatment is not warranted, though 
magnesium therapy may be considered in pregnancy-related NLC.
Supplementary material
Supplementary material is available at Family Practice online.
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